Key points from article :
Biotech startup Range Biotechnologies has secured $5.2 million in seed funding to develop its innovative proteomics technologies for personalized health.
Range Bio's proprietary platform integrates synthetic biology, genomics, and machine learning to analyze genetic data, offering personalized insights and solutions for patients.
The company's focus is on "translational proteomics", or using biomarker panels at scale in real-world applications, not just discovery.
With the funds, Range Bio plans to expand its R&D, recruit talent, and further develop its technology platform.
CEO Brandon Wilson envisions a future where healthcare is proactive and personalized, using molecular infrastructure to monitor dynamic changes in health over time.
The funding round was led by ARTIS Ventures, along with other investors including Pear VC, Page One Ventures, Civilization Ventures, Pillar, Four Cities Capital, Hawktail, and others.
Range Bio aims to overcome current proteomics bottlenecks, such as multiplexing, dynamic range, and throughput, to enable new paradigms in pharmacodynamics, diagnostics, clinical trials, and health screening.
By understanding complex interactions across proteins in the human body, Range Bio's tech could enable a comprehensive view of an individual's health and allow for personalized treatment options.
